February 7, 2014
The landscape of hepatitis C (HCV) management has undergone a near-fundamental transformation over the past couple of years. As new treatment options puff up like popcorn kernels on a hot stove and our understanding of the virus deepens, it's important to revisit what's changed -- and what further changes 2014 may hold in store.
Late in 2013, Andrea Cox, M.D., Ph.D., an associate professor of medicine at Johns Hopkins University School of Medicine, presented an update on HCV coinfection for an audience of HIV care providers. Read on for a summary of key points from her talk, including selected slides (which have been reposted with her permission).
Myles Helfand is the editorial director of TheBody.com and TheBodyPRO.com.
Follow Myles on Twitter: @MylesatTheBody.
The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.
|No Increased Risk of Liver Cancer After Hepatitis C Treatment With Direct-Acting Antivirals|
|This Week in HIV Research: Another Person Possibly Cured of HIV; and Long-Acting Rilpivirine Suppresses HIV in Rectal Tissue|
|This Week in HIV Research: HIV-Related Inflammation May Be Irreversible; and Genetically Engineered T-Cells Resist HIV|
|How Close Are We to a Cure for HIV? A Q&A With HIV Cure Scientific Superstars|
|Dolutegravir and the Central Nervous System: A Top HIV Clinical Development of 2016|